– Quarterly revenue: $5.08 billion, a 6% decrease from Q3 2022;
– Quarterly earnings: $3.61 per share, a 35% decrease from Q3 2022;
– Lowered 2023 revenue guidance for Covid vaccine sales by $4 billion due to omicron variant uncertainty;
– EPS forecast for Q1 is $3.12
Consensus EPS forecast: $3.22
High EPS forecast: $12.53
Low EPS forecast: -$3
Number of estimates: 12
The earnings forecast for 2023 is significantly lower than 2022 due to several factors, such as:
Uncertainty over Covid vaccine sales due to omicron variant;
Increased competition from other mRNA companies;
Higher research and development costs for new products;
– Announced positive data for personalized cancer vaccine candidate in melanoma patients;
– Operating expense increased due to higher research and development costs;
Sources:
(1) https://bing.com/search?q=MRNA+Q4+2022+earning
(2) Moderna misses on earnings as costs rise from surplus production capacity, lower Covid shot demand. https://www.msn.com/en-us/money/companies/moderna-misses-on-earnings-as-costs-rise-from-surplus-production-capacity-lower-covid-shot-demand/ar-AA17QpBQ
(3) Moderna (MRNA) Lags on Q4 Earnings, COVID Jab Sales Down Y/Y. https://www.zacks.com/stock/news/2058315/moderna-mrna-lags-on-q4-earnings-covid-jab-sales-down-yy
(4) Moderna (MRNA) to Report Q4 Earnings: What’s in the Cards?. https://www.nasdaq.com/articles/moderna-mrna-to-report-q4-earnings%3A-whats-in-the-cards
(5) Moderna’s Earnings, Revenue Fall on Fewer Covid Vaccine Sales. https://www.wsj.com/articles/moderna-mrna-q4-earnings-report-2022-8f43fe98?mod=newsviewer_click
(6) Moderna (MRNA) Lags Q4 Earnings and Revenue Estimates. https://finance.yahoo.com/news/moderna-mrna-lags-q4-earnings-131501341.html